Digest Network Come funziona
Network
/
Società
Zu
Non verificato

Zura Bio Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

19 comunicati stampa

Guarda tutti i comunicati
13/11/2025
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0
20/08/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Web e Social Network
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0
14/08/2025
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Mercato azionario
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0
01/07/2025
Zura Bio Announces Chief Financial Officer Transition
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0
27/05/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Zura Bio to Present at the Jefferies Global Healthcare Conference
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0
20/05/2025
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0
08/05/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Sanità
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0
25/03/2025
Mercato azionario
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0
24/02/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Web e Social Network
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0
23/12/2024
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Fonte
Zura Bio Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0